Baricitinib

ABBVIE INC. (NYSE: ABBV) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AbbVie Inc. (NYSE: ABBV)

Retrieved on: 
Wednesday, June 1, 2022
Janus, Lists of action films, District court, Ulcerative colitis, Securities Exchange Act of 1934, Baricitinib, RA, Food, Court, News, The Legal 500, COVID-19 vaccine, Investment, FDA, JAK, Eli Lilly and Company, Ankylosing spondylitis, Cancer, Advertising, Biosimilar, Risk, GLOBE, NYSE, COVID-19, Atopic dermatitis, Rheumatoid arthritis, Labour government, NEW, ABBV, Lists of schools in England, Pfizer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Enzyme, Company, Safety, Tobacco, Pharmaceutical industry, Animal, Security (finance), Tofacitinib, AbbVie, Upadacitinib

NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ABBVIE INC. (NYSE: ABBV) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AbbVie Inc. (NYSE: ABBV)

Retrieved on: 
Tuesday, May 10, 2022
Janus, COVID-19, Investment, Eli Lilly and Company, Ulcerative colitis, The Legal 500, GLOBE, NEW, District court, Securities Exchange Act of 1934, NYSE, Food, Safety, Lists of action films, Atopic dermatitis, Company, ABBV, Risk, Pfizer, FDA, Cancer, Labour government, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Enzyme, Court, Advertising, Lists of schools in England, RA, COVID-19 vaccine, Ankylosing spondylitis, JAK, News, Baricitinib, Rheumatoid arthritis, Biosimilar, Tobacco, Pharmaceutical industry, Animal, Security (finance), Tofacitinib, Upadacitinib, AbbVie

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ABBVIE INC. (NYSE: ABBV) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AbbVie Inc. (NYSE: ABBV)

Retrieved on: 
Thursday, April 28, 2022
Janus, Advertising, Lists of action films, NYSE, ABBV, Securities Exchange Act of 1934, RA, Investment, Eli Lilly and Company, FDA, GLOBE, COVID-19, District court, Court, Baricitinib, Food, Cancer, Labour government, Lists of schools in England, NEW, Biosimilar, COVID-19 vaccine, News, Ulcerative colitis, Rheumatoid arthritis, Enzyme, Pfizer, Ankylosing spondylitis, The Legal 500, Risk, Company, Atopic dermatitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, JAK, Safety, Tobacco, Pharmaceutical industry, Animal, Security (finance), AbbVie, Tofacitinib, Upadacitinib

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

New Spherix Research Suggests Rheumatologists Are Gravitating Towards BMS' Orencia for the Treatment of Rheumatoid Arthritis as JAK Inhibitor Use Declines

Retrieved on: 
Monday, April 11, 2022
Momentum, HCP, Tofacitinib, Nephrology, Etanercept, GSK, Need for Speed, Neurology, MOA, Genentech, Otilimab, BMS, Growth, Overalls, Baricitinib, AbbVie, Upadacitinib, Prescription, Abivax, TNF, Pfizer, Pharming, GM-CSF, Physician, Rheumatology, Movement, Eli Lilly and Company, JAK, IL-6, RA, FDA, Moa, Patient, Mark (given name), Amgen, Pharmaceutical industry, Adalimumab, Abatacept, Tocilizumab

EXTON, Pa., April 11, 2022 /PRNewswire/ -- The US rheumatoid arthritis (RA) biologic and small molecule market has remained relatively stagnant over the past few years, with little change in prescribing habits and a lack of new commercial developments. However, on the heels of recent market events, Spherix experts have noticed an interesting shift in perceptions and intended usage of some of the more mature brands on the market in addition to the JAK inhibitors.

Key Points: 
  • Spherix has been tracking the evolution of the RA treatment landscape on a quarterly basis through their RealTime Dynamixservice since 2015.
  • AbbVie's Humira maintains a strong position as market leader, while Amgen's Enbrel has experienced a slight dip over time.
  • Where there has been some movement in the market is within the JAK inhibitor class.
  • Spherix specifically probed rheumatologists on their preferred alternate MOA when switching from a TNF inhibitor.

Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study

Retrieved on: 
Tuesday, April 20, 2021
Chemical compounds, Organic compounds, Heterocyclic compounds, Anti-inflammatory agents, Azetidines, Baricitinib, Breakthrough therapy, Pyrazoles, Sulfonamides

In both investigational trials, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint of hair regrowth across the two dosing regimens at Week 36 compared to patients treated with placebo.

Key Points: 
  • In both investigational trials, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint of hair regrowth across the two dosing regimens at Week 36 compared to patients treated with placebo.
  • "\nThe BRAVE-AA trial program was designed to evaluate the efficacy and safety of baricitinib in adult patients with severe AA.
  • Based on interim results of the Phase 2 portion of BRAVE-AA1 at Week 12, baricitinib 2-mg and 4-mg once-daily doses were selected for further evaluation in the Phase 3 portion of the study.
  • BRAVE-AA2 is a multicenter, randomized, double-blind, placebo-controlled study evaluating the baricitinib 2-mg and 4-mg dosing regimens versus placebo.

BenevolentAI: Data from Eli Lilly's COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

Retrieved on: 
Thursday, April 8, 2021
Chemical compounds, Organic compounds, Medical specialties, COVID-19, Azetidines, Baricitinib, Breakthrough therapy, Pyrazoles, Sulfonamides, Dexamethasone, Rheumatoid arthritis

The COV-BARRIER results further validate BenevolentAI's AI-derived hypothesis, first published in early February 2020, which prompted additional global trials and investigations into its efficacy as a treatment for critically ill COVID-19 patients.

Key Points: 
  • The COV-BARRIER results further validate BenevolentAI's AI-derived hypothesis, first published in early February 2020, which prompted additional global trials and investigations into its efficacy as a treatment for critically ill COVID-19 patients.
  • In the COV-BARRIER study, baricitinib was given in addition to the standard of care, which included dexamethasone in the majority of patients.
  • The significant reduction in mortality demonstrated in the COV-BARRIER trial follows several published studies confirming baricitnib's therapeutic effect, such as those in EMBO Mol Med , Science Advances , J. Clin.
  • Baricitinib is approved for the treatment of rheumatoid arthritis and other diseases.

BenevolentAI: Data from Eli Lilly's COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

Retrieved on: 
Thursday, April 8, 2021
Chemical compounds, Organic compounds, Medical specialties, COVID-19, Azetidines, Baricitinib, Breakthrough therapy, Pyrazoles, Sulfonamides, Dexamethasone, Rheumatoid arthritis

The COV-BARRIER results further validate BenevolentAI's AI-derived hypothesis, first published in early February 2020, which prompted additional global trials and investigations into its efficacy as a treatment for critically ill COVID-19 patients.

Key Points: 
  • The COV-BARRIER results further validate BenevolentAI's AI-derived hypothesis, first published in early February 2020, which prompted additional global trials and investigations into its efficacy as a treatment for critically ill COVID-19 patients.
  • In the COV-BARRIER study, baricitinib was given in addition to the standard of care, which included dexamethasone in the majority of patients.
  • The significant reduction in mortality demonstrated in the COV-BARRIER trial follows several published studies confirming baricitnib's therapeutic effect, such as those in EMBO Mol Med , Science Advances , J. Clin.
  • Baricitinib is approved for the treatment of rheumatoid arthritis and other diseases.

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation

Retrieved on: 
Thursday, March 18, 2021
Biotechnology, Pharmaceutical, General Health, Health, Medical devices, Infectious diseases, Hospitals, Clinical trials, Medical specialties, Health, Medicine, Intensive care medicine, COVID-19 drug development, Nucleotides, Remdesivir, Acute respiratory distress syndrome, Coronavirus disease, Mechanical ventilation, Treatment and management of COVID-19, Baricitinib, DEVENT (NCT04377620), the Ruxolitinib Expanded Access Program (EAP) in COVID-19, Jakafi® (ruxolitinib), Incyte

More than half of study patients (55%) received remdesivir and 90% of study patients received corticosteroids prior to or during the study.

Key Points: 
  • More than half of study patients (55%) received remdesivir and 90% of study patients received corticosteroids prior to or during the study.
  • The safety profile was generally consistent with hospitalized patients with COVID-19 and consistent with treatment with ruxolitinib.
  • We look forward to discussing the results of the DEVENT study with regulatory authorities in the United States.
  • The protocol will allow eligible patients with severe COVID-19 associated ARDS with disease severity requiring mechanical ventilation to receive ruxolitinib.

Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA

Retrieved on: 
Tuesday, December 15, 2020
Health sciences, Health, Medicine, Clinical research, Arthritis, Rheumatology, Pharmaceutical industry, Coronavirus disease, Baricitinib, Investigational New Drug

The filing of an IND will enable participation of US medical centers in future clinical studies of Rabeximod in Covid-19, rheumatoid arthritis and potential other indications.

Key Points: 
  • The filing of an IND will enable participation of US medical centers in future clinical studies of Rabeximod in Covid-19, rheumatoid arthritis and potential other indications.
  • The IND package is based upon the favorable safety profile of Rabeximod shown in previous Phase 1 and Phase 2a studies.
  • "Filing an IND with the FDA is an important step in the clinical development of Rabeximod.
  • Rabeximod will be evaluated in patients suffering from moderate Covid-19 in need of oxygen treatment but not ventilation support.

Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA

Retrieved on: 
Tuesday, December 15, 2020
Health sciences, Health, Medicine, Clinical research, Arthritis, Rheumatology, Pharmaceutical industry, Coronavirus disease, Baricitinib, Investigational New Drug

The filing of an IND will enable participation of US medical centers in future clinical studies of Rabeximod in Covid-19, rheumatoid arthritis and potential other indications.

Key Points: 
  • The filing of an IND will enable participation of US medical centers in future clinical studies of Rabeximod in Covid-19, rheumatoid arthritis and potential other indications.
  • The IND package is based upon the favorable safety profile of Rabeximod shown in previous Phase 1 and Phase 2a studies.
  • "Filing an IND with the FDA is an important step in the clinical development of Rabeximod.
  • Rabeximod will be evaluated in patients suffering from moderate Covid-19 in need of oxygen treatment but not ventilation support.